Anuradha Roy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2901261/publications.pdf Version: 2024-02-01



ΔΝΠΒΑΡΗΑ ΡΟΥ

#	Article	IF	CITATIONS
1	Repurposing Avasimibe to Inhibit Bacterial Glycosyltransferases. Pathogens, 2022, 11, 370.	2.8	Ο
2	Discovery of small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1320-1326.	5.2	7
3	YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity. Pathogens, 2021, 10, 253.	2.8	7
4	Disrupting interferon-alpha and NF-kappaB crosstalk suppresses IFITM1 expression attenuating triple-negative breast cancer progression. Cancer Letters, 2021, 514, 12-29.	7.2	16
5	Repurposing p97 inhibitors for chemical modulation of the bacterial ClpB–DnaK bichaperone system. Journal of Biological Chemistry, 2021, 296, 100079.	3.4	8
6	High-Throughput Screening (HTS) Technology. , 2021, , 787-799.		1
7	Profiling Anticancer and Antioxidant Activities of Phenolic Compounds Present in Black Walnuts (Juglans nigra) Using a High-Throughput Screening Approach. Molecules, 2020, 25, 4516.	3.8	12
8	Identification and Validation of an Aspergillus nidulans Secondary Metabolite Derivative as an Inhibitor of the Musashi-RNA Interaction. Cancers, 2020, 12, 2221.	3.7	17
9	Bioactivity Profiling of Plant Biodiversity of Panama by High Throughput Screening. Natural Product Communications, 2019, 14, 1934578X1901400.	0.5	5
10	Discovery of Small-Molecule Inhibitors Targeting the E3 Ubiquitin Ligase Activity of the Herpes Simplex Virus 1 ICPO Protein Using an <i>In Vitro</i> High-Throughput Screening Assay. Journal of Virology, 2019, 93, .	3.4	12
11	Challenges with risk mitigation in academic drug discovery: finding the best solution. Expert Opinion on Drug Discovery, 2019, 14, 95-100.	5.0	10
12	Mutant Huntingtinâ€Calmodulin Interaction: Potential Therapeutic Target for Huntington's Disease. FASEB Journal, 2019, 33, 501.16.	0.5	0
13	High-Throughput Screening for Bacterial Glycosyltransferase Inhibitors. Frontiers in Cellular and Infection Microbiology, 2018, 8, 435.	3.9	21
14	How to rekindle drug discovery process through integrative therapeutic targeting?. Expert Opinion on Drug Discovery, 2018, 13, 893-898.	5.0	5
15	Early Probe and Drug Discovery in Academia: A Minireview. High-Throughput, 2018, 7, 4.	4.4	33
16	Cooperative p16 and p21 action protects female astrocytes from transformation. Acta Neuropathologica Communications, 2018, 6, 12.	5.2	47
17	Comparative oncology approach to drug repurposing in osteosarcoma. PLoS ONE, 2018, 13, e0194224.	2.5	22
18	Fluorescence High-Throughput Screening for Inhibitors of TonB Action. Journal of Bacteriology, 2017, 199	2.2	20

Anuradha Roy

#	Article	IF	CITATIONS
19	Development of High-Throughput Screening Assay for Antihantaviral Therapeutics. SLAS Discovery, 2017, 22, 767-774.	2.7	7
20	Holistic Drug Targeting. , 2017, , 65-88.		7
21	Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics. Translational Lung Cancer Research, 2017, 6, 600-610.	2.8	5
22	Identification of novel small molecule Beclin 1 mimetics activating autophagy. Oncotarget, 2017, 8, 51355-51369.	1.8	12
23	Full and Partial Agonism of a Designed Enzyme Switch. ACS Synthetic Biology, 2016, 5, 1475-1484.	3.8	7
24	Targeting a Novel RNA-Protein Interaction for Therapeutic Intervention of Hantavirus Disease. Journal of Biological Chemistry, 2016, 291, 24702-24714.	3.4	18
25	DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nature Cell Biology, 2016, 18, 1233-1243.	10.3	179
26	Identification of a Small Molecule Cyclophilin D Inhibitor for Rescuing AÎ ² -Mediated Mitochondrial Dysfunction. ACS Medicinal Chemistry Letters, 2016, 7, 294-299.	2.8	38
27	DARC: Mapping Surface Topography by Ray-Casting for Effective Virtual Screening at Protein Interaction Sites. Journal of Medicinal Chemistry, 2016, 59, 4152-4170.	6.4	20
28	Targeting Epithelial-Mesenchymal Transition for Identification of Inhibitors for Pancreatic Cancer Cell Invasion and Tumor Spheres Formation. PLoS ONE, 2016, 11, e0164811.	2.5	17
29	Identification and Validation of Novel Small Molecule Disruptors of HuR-mRNA Interaction. ACS Chemical Biology, 2015, 10, 1476-1484.	3.4	120
30	Natural product (â^')â€gossypol inhibits colon cancer cell growth by targeting RNAâ€binding protein Musashiâ€1. Molecular Oncology, 2015, 9, 1406-1420.	4.6	116
31	Chemoresistant Leukemia-Initiating Cell Expansion Is Inhibited By Targeting Oncogenic Self-Renewal. Blood, 2015, 126, 1860-1860.	1.4	2
32	A Cell-Based High-Throughput Screen for Novel Chemical Inducers of Fetal Hemoglobin for Treatment of Hemoglobinopathies. PLoS ONE, 2014, 9, e107006.	2.5	19
33	Expanding the results of a high throughput screen against an isochorismate-pyruvate lyase to enzymes of a similar scaffold or mechanism. Bioorganic and Medicinal Chemistry, 2014, 22, 5961-5969.	3.0	8
34	High Throughput Screening Operations at the University of Kansas. Combinatorial Chemistry and High Throughput Screening, 2014, 17, 387-393.	1.1	3
35	Benzylmorpholine Analogs as Selective Inhibitors of Lung Cytochrome P450 2A13 for the Chemoprevention of Lung Cancer in Tobacco Users. Pharmaceutical Research, 2013, 30, 2290-2302. 	3.5	12
36	Compound Ranking Based on a New Mathematical Measure of Effectiveness Using Time Course Data from Cell-Based Assays. Combinatorial Chemistry and High Throughput Screening, 2013, 16, 168-179.	1.1	5

Anuradha Roy

#	Article	IF	CITATIONS
37	Patent Review. Combinatorial Chemistry and High Throughput Screening, 2011, 14, 303-305.	1.1	0
38	Patent Review. Combinatorial Chemistry and High Throughput Screening, 2011, 14, 642-644.	1.1	0
39	Research Spotlight: The University of Kansas High-Throughput Screening Laboratory. Part I: meeting drug-discovery needs in the heartland of America with entrepreneurial flair. Future Medicinal Chemistry, 2011, 3, 789-795.	2.3	5
40	Research Spotlight: The University of Kansas High-Throughput Screening Laboratory. Part II: enabling collaborative drug-discovery partnerships through cutting-edge screening technology. Future Medicinal Chemistry, 2011, 3, 1101-1110.	2.3	6
41	Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making. Current Pharmaceutical Biotechnology, 2010, 11, 764-778.	1.6	63